News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
703,369 Results
Type
Article (41755)
Company Profile (327)
Press Release (661287)
Section
Business (210098)
Career Advice (2071)
Deals (36567)
Drug Delivery (95)
Drug Development (82767)
Employer Resources (171)
FDA (16476)
Job Trends (15353)
News (355327)
Policy (33813)
Tag
Academia (2574)
Alliances (51039)
Alzheimer's disease (1235)
Approvals (16395)
Artificial intelligence (132)
Bankruptcy (362)
Best Places to Work (11613)
Biotechnology (210)
Breast cancer (111)
Cancer (971)
Cardiovascular disease (86)
Career advice (1734)
Cell therapy (211)
Clinical research (65491)
Collaboration (341)
Compensation (173)
COVID-19 (2593)
Data (911)
Diabetes (140)
Diagnostics (6192)
Drug pricing (86)
Earnings (86054)
Employer resources (149)
Events (111902)
Executive appointments (261)
FDA (16943)
Funding (303)
Gene therapy (163)
GLP-1 (596)
Government (4439)
Healthcare (18841)
Infectious disease (2671)
Inflammatory bowel disease (106)
Interviews (319)
IPO (16551)
Job creations (4052)
Job search strategy (1485)
Layoffs (429)
Legal (8314)
Lung cancer (158)
Manufacturing (166)
Medical device (13237)
Medtech (13242)
Mergers & acquisitions (20042)
Metabolic disorders (386)
Neuroscience (1486)
NextGen Class of 2024 (6622)
Non-profit (4511)
Northern California (1275)
Obesity (229)
Opinion (200)
Patents (99)
People (58107)
Pharmaceutical (92)
Phase I (20236)
Phase II (28806)
Phase III (21641)
Pipeline (256)
Postmarket research (2643)
Preclinical (8630)
Radiopharmaceuticals (239)
Rare diseases (197)
Real estate (6238)
Regulatory (22296)
Research institute (2356)
Resumes & cover letters (358)
Southern California (1142)
Startups (3710)
United States (12248)
Vaccines (558)
Weight loss (176)
Date
Today (246)
Last 7 days (945)
Last 30 days (3232)
Last 365 days (36127)
2024 (31439)
2023 (40631)
2022 (51799)
2021 (56331)
2020 (54797)
2019 (47401)
2018 (35772)
2017 (33140)
2016 (32664)
2015 (38619)
2014 (32519)
2013 (27632)
2012 (29734)
2011 (30489)
2010 (28497)
Location
Africa (776)
Arizona (194)
Asia (39907)
Australia (6376)
California (2889)
Canada (1204)
China (222)
Colorado (128)
Connecticut (129)
Europe (84928)
Florida (409)
Georgia (102)
Illinois (320)
Indiana (192)
Kansas (95)
Maryland (544)
Massachusetts (2374)
Michigan (145)
Minnesota (255)
New Jersey (867)
New York (867)
North Carolina (691)
Northern California (1275)
Ohio (129)
Pennsylvania (776)
South America (1157)
Southern California (1142)
Texas (408)
Washington State (335)
703,369 Results for "wex pharmaceuticals inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Virios Therapeutics, Inc. and Wex Pharmaceuticals, Inc. Announce Business Combination to Form Dogwood Therapeutics, Inc. (Nasdaq: “DWTX”)
October 8, 2024
·
14 min read
Wex Pharmaceuticals Inc. Commences Its Quantitative Sensory Testing Clinical Trial Evaluating the Impact of Halneuron(R) on Healthy Volunteers’ Sensory Perceptions
WEX Pharmaceuticals Inc. (“WEX” or the “Company”), a biotechnology company developing Halneuron® (Tetrodotoxin or TTX) for pain, announced that it has commenced its Quantitative Sensory Testing (QST) clinical trial and is actively recruiting participants into this clinical trial.
December 11, 2023
·
5 min read
Drug Development
Wex Pharmaceuticals Inc. Enrolls the First Patient in The Phase 2b Clinical Trial Evaluating the Efficacy and Safety of Halneuron(R) In the Treatment of Chemotherapy-Induced Neuropathic Pain
WEX Pharmaceuticals Inc., a biotechnology company developing Halneuron® for pain, announced that the first patient has been dosed in its Phase 2B clinical trial evaluating the efficacy and safety of Tetrodotoxin in the treatment of Chemotherapy-Induced Neuropathic Pain.
January 3, 2023
·
6 min read
Press Releases
Verrica Pharmaceuticals Announces Litigation Settlement with Dormer Laboratories, Inc.
Verrica Pharmaceuticals Inc. today announced the settlement of litigation with Dormer Laboratories, Inc. (“Dormer Labs”).
July 1, 2024
·
5 min read
Press Releases
Madrigal Pharmaceuticals, Inc. Announces Participation at Three Upcoming Investor Conferences
November 7, 2024
·
1 min read
BioMidwest
Nika Pharmaceuticals, Inc. (NIKA) Presents Its Business Strategy
Nika Pharmaceuticals, Inc. introduces its plans to develop the company into a sustainable business project that will consistently grow, bring good profits and provide dividends to its shareholders.
June 3, 2024
·
5 min read
BioMidwest
Bexion Pharmaceuticals, Inc. to Present at BIO International Convention 2024
Bexion Pharmaceuticals, Inc. announced that the Company will present at the 2024 Biotechnology Innovation Organization International Convention taking place June 3-6, 2024, in San Diego, California.
May 31, 2024
·
2 min read
Deals
Future Pak Issues Enhanced and Final Proposal to Acquire Vanda Pharmaceuticals Inc.
Future Pak, LLC and its affiliates announced that it has submitted a final attempt to engage with Vanda Pharmaceuticals Inc. in a good faith effort to acquire all outstanding shares of Vanda.
June 13, 2024
·
4 min read
Press Releases
NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) and HOPE Therapeutics, Inc. Announce Participation at the ThinkEquity Conference October 30, 2024
October 24, 2024
·
4 min read
Pharm Country
NRx Pharmaceuticals, Inc. (Nasdaq:NRXP) to Participate in the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference on June 27, 2024
NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) (“NRx Pharmaceuticals”, the “Company”), a clinical stage pharmaceutical company, today announced that management will participate in the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference on Thursday, June 27, 2024.
June 20, 2024
·
2 min read
1 of 70,337
Next
